Navigation Links
Johns Hopkins Begins Aggressive Screening for 'superbugs' in Children

Safety study triggered decision to go beyond standard monitoring and testing schedules//
Infection control and critical care experts at The Johns Hopkins Hospital have ordered testing for the two most common hospital superbugs for every child admitted to its pediatric intensive care unit.

The more stringent admission screening methods for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) go well beyond standard hospital practices, where tests are only ordered after symptoms or early signs of infection appear.

The new hospital practice was introduced March 1 after a study conducted at Hopkins last year showed that more frequent screening detected many more carriers of the germs before their presence led to infection or the germs spread to others.

Admission screening is already standard at Hopkins for adults admitted to intensive care units.

Health experts fear spread of these particular bacteria because they have developed resistance to the antibiotic drugs most commonly used to combat them. Though infections caused by these bacteria are rarely fatal, carriers of either bug are at greater risk for more dangerous infections.

Results from the study, to be presented April 16 at the annual meeting of the Society of Health Care Epidemiology of America (SHEA) in Baltimore, are believed among the first to make a case for better screening in efforts to slow spread of the germs in hospitalized children.

The study compared the effectiveness of weekly screening to current practices for ordering tests and found the weekly model to be many times more effective than standard risk monitoring, in which the highly contagious bacteria are looked for after patients develop skin rash, fever or pain.

Weekly swab testing and bacterial growth cultures were done on nearly 330 patients in the hospital's pediatric intensive care unit for four months. Re sults were compared to findings of cultures obtained from patients showing possible signs or symptoms of infection. All patients were under age 18.

The weekly testing for MRSA, the most common superbug, detected more than half of young patients who were carrying the germ (54 percent, or one and a half times as many) than were detected through routine testing, which missed 35 percent of those with MRSA. Results for detecting VRE, a lesser known but still common superbug, were six times higher with weekly testing than with routine testing, which missed 82 percent of those with VRE. Like most bacteria, hospital superbugs are picked up through direct contact, by touching someone or a surface with it.

"The results were quite clear to us: Aggressive patient safety programs should consider testing on admission as standard practice," says study senior author and hospital epidemiologist Trish Perl, M.D. Perl and her team, however, will wait for evidence of improved patient safety before making any national recommendations to government agencies and other hospitals.

Perl is past president of SHEA and will be presenting at the four-day conference, expected to attract 1,200 infectious disease specialists, epidemiologists, nurses and hospital administrators to the city.

"We need to find patients who have these bacteria on them and who, as such, are not only at risk of personal infection, but also pose a serious threat of infection to other patients and hospital staff," she says.

According to Perl, a professor of medicine and pathology at The Johns Hopkins University School of Medicine, patients found to be infected or to be a carrier before infection has set in are placed in isolation for the remainder of their stay. Wound care is done only in designated, confined treatment spaces or separate rooms, and hospital staff must take special precautions between treatments, such as cleaning equipment and furniture with s trong disinfectants and wearing disposable gloves, masks and gowns.

"Children are more vulnerable to the problem of antibiotic resistance because their bodies are not fully developed to fight off illness and because fewer drugs are FDA approved for use in children," says Aaron Milstone, M.D., a pediatric infectious diseases research fellow at Hopkins who led the study.

Vancomycin (Vancocin) is currently the only FDA-approved drug for MRSA in children, and only one drug, linezolid (Zyvox), is approved in pediatrics for VRE.

Milstone says children admitted to Hopkins are increasingly identified as harboring MRSA or VRE, with recent reports from the intensive care unit showing four times as many children with MRSA and twice as many with VRE than five years ago. These reports and others led the Hopkins team to conduct the study. In 2006, the Joint Commission on Accreditation of Healthcare Organizations (now known only as the Joint Commission) estimated that 70 percent of the bacteria that cause infections for 2 million hospitalized Americans each year are resistant to at least one of the drugs most commonly used to treat them.

Source-Eurekalert/V
'"/>




Related medicine news :

1. Craig Newschaffer of Johns Hopkins Bloomberg School of Public Health in Baltimore.
2. Johns Hopkins Computer Scientists Unravel Language Of Surgery
3. Gene Hunters at Johns Hopkins Close In On Lou Gehrigs Disease
4. Johns Hopkins Medicine Trustees Support Smoking Ban In Public Spaces
5. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
6. John Hopkins CGHH program provides Global Health education
7. A new study by John Hopkins University proposes formula for good health
8. Genetic Experts of Hopkins Assists In Identifying Hurricane Katrina Victims
9. Craig Newschaffer of Johns Hopkins Bloomberg School of Public Health in Baltimore.
10. Diabetes - New Treatment Approach At John Hopkins
11. Cardiovascular Diseases in India To be Studied Jointly By John Hopkins And Apollo Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: